Modulation of Prion Protein Oligomerization, Aggregation, and β-sheet Conversion by 4,4′-Dianilino-1,1′-binaphthyl-5,5′-sulfonate (bis-ANS)*

The prion protein (PrP) is the major agent implicated in the diseases known as transmissible spongiform encephalopathies. The onset of transmissible spongiform encephalopathy is related to a change in conformation of the PrPC, which loses most of its α-helical content, becoming a β-sheet-rich protein, known as PrPSc. Here we have used two Syrian hamster prion domains (PrP 109–141 and PrP 109–149) and the murine recombinant PrP (rPrP 23–231) to investigate the effects of anilino-naphtalene compounds on prion oligomerization and aggregation. Aggregation in the presence of bis-ANS (4,4′-dianilino-1,1′-binaphthyl-5,5′-sulfonate), ANS (1-anilinonaphthalene-8-sulfonate), and AmNS (1-amino-5-naphtalenesulfonate) was monitored. Bis-ANS was the most effective inhibitor of prion peptide aggregation. Bis-ANS binds strongly to rPrP 23–231 leading to a substantial increase in β-sheet content and to limited oligomerization. More strikingly, the binding of bis-ANS to full-length rPrP is diminished by the addition of nanomolar concentrations of oligonucleotides, demonstrating that they compete for the same binding site. Thus, bis-ANS displays properties similar to those of nucleic acids, causing oligomerization and conversion to β-sheet (Cordeiro, Y., Machado, F., Juliano, L., Juliano, M. A., Brentani, R. R., Foguel, D., and Silva, J. L. (2001) J. Biol. Chem. 276, 49400–49409). This dual effect of bis-ANS on prion protein makes this compound highly important to sequester crucial conformations of the protein, which may be useful to the understanding of the disease and to serve as a lead for the development of new therapeutic strategies.

[1]  S. Supattapone,et al.  RNA molecules stimulate prion protein conversion , 2003, Nature.

[2]  B. Caughey,et al.  Prion diseases: A nucleic-acid accomplice? , 2003, Nature.

[3]  J. Esko,et al.  Cellular Heparan Sulfate Participates in the Metabolism of Prions* , 2003, Journal of Biological Chemistry.

[4]  B. Caughey,et al.  New Inhibitors of Scrapie-Associated Prion Protein Formation in a Library of 2,000 Drugs and Natural Products , 2003, Journal of Virology.

[5]  R. Rubenstein,et al.  Small, highly structured RNAs participate in the conversion of human recombinant PrP(Sen) to PrP(Res) in vitro. , 2003, Journal of molecular biology.

[6]  D. Dormont,et al.  A novel generation of heparan sulfate mimetics for the treatment of prion diseases. , 2003, The Journal of general virology.

[7]  P. Lansbury,et al.  Dissociation of amyloid fibrils of α-synuclein and transthyretin by pressure reveals their reversible nature and the formation of water-excluded cavities , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[8]  J. Kelly,et al.  Hydration and packing are crucial to amyloidogenesis as revealed by pressure studies on transthyretin variants that either protect or worsen amyloid disease. , 2003, Journal of molecular biology.

[9]  F. Cohen,et al.  Potent inhibition of scrapie prion replication in cultured cells by bis-acridines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[10]  P. Follette.  Prion Disease Treatment's Early Promise Unravels , 2003, Science.

[11]  C. Masters,et al.  Quinacrine does not prolong survival in a murine Creutzfeldt‐Jakob disease model , 2002, Annals of neurology.

[12]  P. Nandi,et al.  DNA-induced partial unfolding of prion protein leads to its polymerisation to amyloid. , 2002, Journal of molecular biology.

[13]  G. Forloni,et al.  Tetracyclines affect prion infectivity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Gasset,et al.  Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu(II) bridges. , 2002, Journal of molecular biology.

[15]  C. Yu,et al.  Influence of backbone conformation on protein aggregation. , 2002, Journal of the American Chemical Society.

[16]  Y. Cordeiro,et al.  DNA Converts Cellular Prion Protein into the β-Sheet Conformation and Inhibits Prion Peptide Aggregation* , 2001, The Journal of Biological Chemistry.

[17]  V. Uversky,et al.  Stabilization of Partially Folded Conformation during α-Synuclein Oligomerization in Both Purified and Cytosolic Preparations* , 2001, The Journal of Biological Chemistry.

[18]  F E Cohen,et al.  Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  A. Fersht,et al.  The binding of bis-ANS to the isolated GroEL apical domain fragment induces the formation of a folding intermediate with increased hydrophobic surface not observed in tetradecameric GroEL. , 2001, Biochemistry.

[20]  B. Caughey,et al.  Interactions between prion protein isoforms: the kiss of death? , 2001, Trends in biochemical sciences.

[21]  B. Chesebro,et al.  Sulfated glycans and elevated temperature stimulate PrPSc‐dependent cell‐free formation of protease‐resistant prion protein , 2001, The EMBO journal.

[22]  G. Weber,et al.  Virus inactivation by anilinonaphthalene sulfonate compounds and comparison with other ligands. , 2000, Biochemical and biophysical research communications.

[23]  D. Foguel,et al.  The preaggregated state of an amyloidogenic protein: hydrostatic pressure converts native transthyretin into the amyloidogenic state. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[24]  B. Caughey,et al.  Lysosomotropic Agents and Cysteine Protease Inhibitors Inhibit Scrapie-Associated Prion Protein Accumulation , 2000, Journal of virology.

[25]  I. Gilbert,et al.  Screening Congo Red and its analogues for their ability to prevent the formation of PrP-res in scrapie-infected cells. , 2000, The Journal of general virology.

[26]  F. Cohen,et al.  Elimination of prions by branched polyamines and implications for therapeutics. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  B. Caughey,et al.  Novel therapeutic uses for porphyrins and phthalocyanines in the transmissible spongiform encephalopathies. , 1999, Current opinion in microbiology.

[28]  C. Weissmann,et al.  Molecular Genetics of Transmissible Spongiform Encephalopathies* , 1999, The Journal of Biological Chemistry.

[29]  Stanley B. Prusiner,et al.  Nobel Lecture: Prions , 1998 .

[30]  R. Gabizon,et al.  The Anti-prion Activity of Congo Red , 1998, The Journal of Biological Chemistry.

[31]  K Wüthrich,et al.  Human prion proteins expressed in Escherichia coli and purified by high‐affinity column refolding , 1997, FEBS letters.

[32]  Fred E. Cohen,et al.  Conformational Transformations in Peptides Containing Two Putative α-Helices of the Prion Protein , 1995 .

[33]  P. Horowitz,et al.  Exposure of Hydrophobic Surfaces on the Chaperonin GroEL Oligomer by Protonation or Modification of His-401 (*) , 1995, The Journal of Biological Chemistry.

[34]  F. Cohen,et al.  Prion protein gene variation among primates. , 1995, Journal of molecular biology.

[35]  J. King,et al.  Inhibition of viral capsid assembly by 1,1'-bi(4-anilinonaphthalene-5-sulfonic acid). , 1993, Biochemistry.

[36]  P. Roller,et al.  Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. , 1993, The Journal of biological chemistry.

[37]  G. Lorimer,et al.  Reversible dissociation and conformational stability of dimeric ribulose bisphosphate carboxylase. , 1993, Biochemistry.

[38]  B. Caughey,et al.  Potent Inhibition of Scrapie‐Associated PrP Accumulation by Congo Red , 1992, Journal of neurochemistry.

[39]  J. Silva,et al.  Dissociation of a native dimer to a molten globule monomer. Effects of pressure and dilution on the association equilibrium of arc repressor. , 1992, Journal of molecular biology.

[40]  P. Horowitz,et al.  Bis(1,8-anilinonaphthalenesulfonate). A novel and potent inhibitor of microtubule assembly. , 1984, The Journal of biological chemistry.